Logo

Merck's Keytruda (pembrolizumab) Receives FDA's Expanded Monotherapy Label Approval for Patients with 1L Stage III Non-Small Cell Lung Cancer (NSCLC)

Share this

Merck's Keytruda (pembrolizumab) Receives FDA's Expanded Monotherapy Label Approval for Patients with 1L Stage III Non-Small Cell Lung Cancer (NSCLC)

Shots:

  • The approval is based on P-III KEYNOTE-042 trial results assessing Keytruda (200mg- q3w) vs CT in 1274 patients in ratio (1:1) with 1L stage III whose tumors expressed PD-L1 with TPS ≥1% and who had not received prior systemic treatment for metastatic NSCLC
  • P-III KEYNOTE-042 study results: @ TPS ≥1%- TPS ≥50% mOS (16.7- 20.0 vs 12.1- 12.2mos.); mPFS (5.4- 7.1 vs 6.5- 6.4mos.); DOR @≥12mos.- ≥18 mos. (47%- 42% vs 16%- 17%)- (26%- 25% vs 6%- 5%); ORR (27%- 39% vs 27%- 32%)  
  • Keytruda (pembrolizumab) 100mg is an anti-PD-1 therapy involves blocking of the interaction between PD-1 and its ligands i.e PD-L1 & PD- L2 and is evaluated in 900 trial globally in oncology

Ref: Merck & Co | Image: Merck

 

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions